This echoes the findings from preclinical models showing that tumor microenvironment therapeutic reprogramming via CXCR4 blockade, CD40 agonists, or TGF-β inhibition enhances Tc recruitment and restores anti-tumor activity [27,28,29,39,40,41]. Here, TGFB1 is linked to neoplasm.